Rilonacept: IL-1 inhibitor treatment of autoimmune diseases treatment of inflammatory disorders

Drugs of the Future

Volumn 32, Issue 5, 2007, Pages 411-416

  Sorbera, L A ^a   Bozzo, J ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACZ 885; AJULEMIC ACID; AMG 108; AN 2728; CORTICOSTEROID; DOM 0400; ETANERCEPT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; ITF 2375; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY INTERLEUKIN 1 RECEPTOR; MONOCLONAL ANTIBODY INTERLEUKIN 2 RECEPTOR; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

ADULT ONSET STILL DISEASE; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; INJECTION SITE BURNING; INJECTION SITE DISCOMFORT; INJECTION SITE REACTION; INTERSTITIAL CYSTITIS; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; MAXIMUM ALLOWABLE CONCENTRATION; MUCKLE WELLS SYNDROME; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

EID: 34547760901     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.05.1100314     Document Type: Article

References (26)

1. Prous Science Disease Briefings: Rheumatoid Arthritis (online publication). Updated 2007.
2. Dinarello, C.A. Proinflammatory cytokines. Chest 2000, 118(2): 503-8.
3. Gaffen, S.L. Biology of recently discovered cytokines: Interleukin-17 - A unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Rev Ther 2004, 6(6): 240-7.
4. Dinarello, C.A. Blocking IL-1 in systemic inflammation. J Exp Med 2005, 201(9): 1355-9.
5. Dinarello, C.A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004, 4(4): 378-85.
6. Dinarello, C.A. The many worlds of reducing interleukin-1. Arthritis Rheum 2005, 52(7): 1960-7.
7. Economides, A.N., Carpenter, L.R., Rudge, J.S. et al. Cytokine traps: Multi-component, high-affinity blockers of cytokine action. Nat Med 2003, 9(1): 47-52.
8. Fast track designation for IL-1 trap program. DailyDrugNews.com, June 2, 2006.
9. Regeneron Pharmaceuticals reports Q4 and full year 2006 R&D highlights. Regeneron Pharmaceuticals Press Release, March 1, 2007.
10. Rydgren, T., Bengtsson, D., Sandler, S. Complete protection against interleukin-1β-induced functional suppression and cytokine-mediated cytotoxicity in rat pancreatic islets in vitro using an interleukin-1 cytokine trap. Diabetes 2006, 55(5): 1407-12.
11. Wang, L.-H., Chen, J., Krueger, P. et al. Murine IL-1 trap reduces neointimal hyperplasia in vivo. Circulation [78th Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 1512.
12. Wang, L.-H., Chen, J., Krueger, P. et al. IL-1 trap blocks complex plaque formation in a mouse atherosclerosis model combining hyperlipidemia and inflammation. 69th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005, Abst 1248.
13. Guler, H.-P., Caldwell, J., Littlejohn, T. III et al. A phase 1, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Arthritis Rheum [65th Annu Sci Meet Am Coll Rheumatol (Nov 10-15, San Francisco) 2001] 2001, 44(9, Suppl.): S370.
14. Roberts, W., Stahl, N., Grimes, I. et al. Interleukin-1 trap provides prolonged suppression of the cardiovascular risk factor C-reactive protein in healthy adults. Circulation [78th Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 470.
15. Guler, H.P., Caldwell, J.R., Fleischman, R.M. et al. Weekly treatment with IL-1 trap is well tolerated and improves ACR criteria in patients with active rheumatoid arthritis. Eur Leag Against Rheum Congr (June 12-15, Stockholm) 2002, Abst OP0090.
16. Bingham, C.O. III, Genovese, M.C., Moreland, L.W., Grimes, I., Parsey, M.V. Results of a phase II study of IL1-trap in moder ate to severe rheumatoid arthritis. 68th Annu Sci Meet Am Coll Rheumatol (Oct 16-21, San Antonio) 2004, Abst 517.
17. Garnero, P., Charni, N., Voorzanger-Rousselot, N., Radin, A., Bingham, C.O. Effects of IL-1 trap on biochemical markers of inflammation and joint tissue breakdown in patients with rheumatoid arthritis. Arthritis Rheum [69th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005] 2005, 52(9, Suppl.): Abst 868.
18. Lovell, D.J., Giannini, E.H., Kimura, Y. et al. Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum [70th Annu Sei Meet Am Coll Rheumatol (Nov 10-15, Washington, D.C.) 2006] 2006, 54(9, Suppl.): Abst 718.
19. Lovell, D., Giannini, E., Kimura, Y. et al. Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Annu Eur Congr Rheumatol (EULAR) (June 21-24, Amsterdam) 2006, Abst LB0005.
20. Goldbach-Mansky, R Wilson, M., Snyder, C. et al. Differential response to the long acting IL-1 inhibitor IL-1 trap in 2 patients with adult onset Still's disease (AOSD). Annu Eur Congr Rheumatol (EULAR) (June 21-24, Amsterdam) 2006, Abst THU0485.
21. Canna, S., Gelabert, A., Aksentijevich, I. et al. Treatment of 4 patients with cryopyrin-associated periodic syndromes with the long-acting IL-1 inhibitor IL-1 trap. 69th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005, Abst 672.
22. Canna, S., Gelabert, A., Aksentijevich, I. et al. Treatment of 4 patients with cryopyrin-associated periodic syndromes with the long acting IL-1 inhibitor IL-1 trap. Annu Eur Congr Rheumatol (EULAR) (June 8-11, Vienna) 2005, Abst OP0154.
23. Hoffman, H.M., Weinstein, S.P., Amar, N.J. et al. The first placebo-controlled trial in cryopyrin-associated periodic syndromes (CAPS): IL-1 trap (rilonacept) markedly reduces clinical and laboratory abnormalities in patients with familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). 63rd Annu Meet Am Acad Allergy Asthma Immunol (AAAAI) (Feb 23-27, San Diego) 2007, Abst LB7.
24. Interleukin-1 trap to treat autoinflammatory disease (NCT00094900). ClinicalTrials.gov Web site, May 21, 2007.
25. IL-1 trap treatment of CIAS1 associated periodic syndromes (CAPS) (NCT00288704). ClinicalTrials.gov Web site, May 21, 2007.
26. Rilonacept to improve artery function in patients with atherosclerosis (NCT00417417). ClinicalTrials.gov Web site, May 21, 2007.